|
WO2021052838A1
|
|
Diffusion-weighted magnetic resonance imaging
|
|
WO2020260870A1
|
|
Exd2 inhibitor for treating cancer
|
|
WO2020099886A1
|
|
Lox inhibitors
|
|
WO2021047783A1
|
|
Vs-6063 in combination with ch5126766 for the treatment of cancer
|
|
CN112243440A
|
|
Hexahydroxypyrrolo [3,4-c ] pyrrole derivatives useful as LOX inhibitors
|
|
WO2019229259A1
|
|
Materials and methods for monitoring the development of resistance of cancers to treatment
|
|
AU2019220440A1
|
|
Patient classification and prognostic method
|
|
WO2019073251A1
|
|
Lysyl oxidase inhibitors
|
|
AU2018315434A1
|
|
Materials and methods for stratifying and treating cancers
|
|
CN110753542A
|
|
Method and medical use
|
|
CN110799183A
|
|
Method and medical use
|
|
WO2018228990A1
|
|
Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer
|
|
WO2018224536A1
|
|
Parp inhibitors for use in treating cancer
|
|
WO2019096397A1
|
|
Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder
|
|
AU2017286618A1
|
|
X-ray micro-beam production and high brilliance x-ray production
|
|
US2020234472A1
|
|
Method for producing a weighted magnetic resonance image
|
